| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$647.7M | ROE | −310.75% |
| Net Margin | — | ROIC | −804.34% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Biohaven is a biopharmaceutical company developing treatments across immunology, neuroscience, and oncology worldwide. Its pipeline includes BHV-1300 for Graves' disease and rheumatoid arthritis, BHV-1400 for IgA nephropathy, BHV-8000 for Parkinson's disease, Opakalim for focal epilepsy, BHV-2100 for pain disorders, and BHV-2000 for obesity, among other candidates at various clinical stages. It is also developing BHV-1510 for advanced or metastatic epithelial cancer.
| Market Cap | $2.02B | Trading Days | 2171 |
| 52W High | 18.57 |
| 52W Low | 7.48 |
| % Off High | −27.66% |
| YTD | 18.95% | 1Y | 4.68% |
| 3Y | −32.44% | 5Y | −89.35% |
| Since incept. (ann.) | −2.83% |
| Ann. Volatility (1Y) | 92.62% | Ann. Volatility (3Y) | 78.07% |
| Sharpe (1Y) | 0.52 | Sharpe (3Y) | 0.25 |
| Max Drawdown (1Y) | −56.99% | Max Drawdown (3Y) | −86.96% |
| Beta (3Y, vs SPY) | 1.43 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | $2.01B | — |
| RAPP | Rapport Therapeutics, Inc. | $2.01B | — |
| ZBIO | Zenas BioPharma, Inc. | $2.04B | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.05B | — |
| URGN | UroGen Pharma Ltd. | $1.99B | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.98B | 24.4 |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.07B | 13.2 |
| PGEN | PRECIGEN, INC. | $1.97B | — |
| IMUX | IMMUNIC, INC. | $2.08B | — |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B |
| 7.2 |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.14B | — |